154140-56-4

Basic information

• Product Name: 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane
• Synonyms: 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane;1-(2-Diazoethyl)-4,5-diMethoxy-2-nitrobenzene
• CAS NO: 154140-56-4
• Molecular Weight: 0
• Mol File: 154140-56-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane(154140-56-4)
• EPA Substance Registry System: 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane(154140-56-4)

Safety Data

• Hazardous Substances Data: 154140-56-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(4,5-dimethoxy-2-nitrophenyl)diazoethane is used as a key intermediate in the synthesis of various organic compounds. Its unique structure, which includes nitro and dimethoxy groups, allows it to participate in a range of chemical reactions, making it a valuable asset in the creation of diverse molecules.
Used in Laboratory Experiments:
As a reagent, 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane is employed in numerous laboratory experiments, particularly those involving diazo coupling reactions. Its ability to form azo compounds makes it a useful tool for researchers in the field of organic chemistry.
Used in Biochemical Research:
1-(4,5-dimethoxy-2-nitrophenyl)diazoethane has been studied for its potential as a photoaffinity labeling reagent in biochemical research. This application could aid in the identification and characterization of various biomolecules, furthering our understanding of biological processes.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, the compound's potential use in the pharmaceutical industry could be inferred due to its involvement in organic synthesis and biochemical research. It may contribute to the development of new drugs or drug candidates by providing novel chemical structures or acting as a reagent in the synthesis of pharmaceutical compounds.
Safety Precautions:
Given the reactivity of 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane, it is crucial to handle 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane with caution in laboratory settings. Proper safety measures, including the use of personal protective equipment and adherence to established safety protocols, should be implemented to minimize potential hazards.

InChI:InChI=1/C10H11N3O4/c1-6(12-11)7-4-9(16-2)10(17-3)5-8(7)13(14)15/h4-5H,1-3H3

Upstream product

• 4101-32-0 4',5'-dimethoxy-2'-nitroacetophenone 
• 123642-61-5 4,5-dimethoxy-2-nitroacetophenone hydrazone 

Relevant articles and documents

Caged agonist of P2Y1 and P2Y12 receptors for light-directed facilitation of platelet aggregation

We have prepared a caged form (MRS2703) of a potent dual agonist of the P2Y1 and P2Y12 nucleotide receptors, 2-MeSADP, by blocking the β-phosphate group with a 1-(3,4-dimethyloxyphenyl)eth-1-yl phosphoester. Although MRS2703 is itsel

A caged doxycycline analogue for photoactivated gene expression

High potential: High-resolution transgene expression in two biological applications demonstrates the potential of a photoactivated gene-expression technique. Irradiation of one half of a transgenic tobacco leaf produced a sharp boundary of reporter gene e

Caged NADP and NAD

Provided are caged NADP and NAD compounds. The invention includes two types of caged NAD and NADP (NAD/P) analogs, each type having a different caging group binding at a different site on the molecule: Phosphate-caged DMNPE-NAD/P and nicotinamide-caged CNB-NAD/P. Both types of caged molecules are designed to be inactive in their caged configurations and activated upon photolysis of the caging group. In some applications, the different types of caged compounds may exhibit biochemically distinct activities. For example, "catalytically caged" NAD/P compounds according to the present invention may bind to an enzyme but not allow turnover prior to photolytic activation. This type of compound has the advantage, when used as a photolytic trigger for time-resolved studies, that it is bound to the enzyme active site prior to photolysis so that no additional diffusion or binding events are necessary to form the Michaelis complex. The present invention also provides NAD/P compounds which may be "affinity caged," having no interaction with the enzyme prior to photolysis. In addition, the invention provides methods of synthesizing caged NAD and NADP and methods of using these compounds in biomedical research applications. -GOVT PAR This invention was made with Government support under Grant (Contract) No. 04200 awarded by the National Science Foundation. The Government has certain rights to this invention.

Syntheses of Phospholipids Containing 2-Nitrobenzyl Ester Moieties at the Terminals of Alkyl Chains and Properties of Photodegradable Liposomes from the Lipids

Phospholipid 1a bearing 2-nitrobenzyl ester moieties as a photocleavable group at the terminal of alkyl chains was synthesized from the corresponding terminal carboxy-bearing phospholipid 2 by the reaction with 2-nitrophenyl-substituted diazomethane. Phospholipid, 1b bearing α-methyl-2-nitrobenzyl group, 1c bearing 4,5-dimethoxy-2-nitrobenzyl group, and 1d bearing α-methyl-4,5-dimethoxy-2-nitrobenzyl group were similarly synthesized by the use of the respective diazo compounds. The order of photolysis rates of 2-nitrobenzyl ester linkage of phospholipids by ultrahigh-pressure mercury lamp is 1b≥1d > 1a > 1c. Liposomes of 1a-1d containing calcein in the inner aqueous layer were prepared by vortexing, sonication, and gel-filtration. UV irradiation resulted in fast release of the entrapped fluorescence dye. The order of release rates : 1b≥1d > 1c> 1a is consistent with that of photolysis rates except for 1c, which has poor retention of the dye.